Tim Meyer
Impact in
- Hepatology top 0.05%
- Hepatocellular Carcinoma Treatment and Prognosis
- Oncology top 0.2%
- Pancreatic and Hepatic Oncology Research
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
Papers in
- Hepatology 83
- Hepatocellular Carcinoma Treatment and Prognosis 80
- Oncology 77
- Lung Cancer Research Studies 25
- Cancer Immunotherapy and Biomarkers 13
- Pancreatic and Hepatic Oncology Research 13
- Co-authors
- Arndt Vogel (12 shared papers)Andrew Kenneth Burroughs (16 shared papers)Anna Lena Saborowski (3 shared papers)Gonzalo Sapisochín (2 shared papers)Riad Salem (1 shared paper)Josep Maria Llovet (10 shared papers)Gordon J.S. Rustin (3 shared papers)Bruno Sangro (13 shared papers)
- Journals
- Annals of Oncology (28 papers)Journal of Hepatology (25 papers)British Journal of Cancer (14 papers)Clinical Cancer Research (9 papers)European Journal of Cancer (8 papers)
- Partner nations
- United KingdomUnited StatesGermany
In The Last Decade
Tim Meyer
223 papers receiving 24.3k citations
Tim Meyer's Hit Papers
Peers
Comparison fields: 5 of 140
- Hepatology 9.8k
- Oncology 7.9k
- Cancer Research 2.8k
- Epidemiology 5.3k
- Pathology and Forensic Medicine 2.0k
Countries citing papers authored by Tim Meyer
This map shows the geographic impact of Tim Meyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tim Meyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tim Meyer more than expected).
Fields of papers citing papers by Tim Meyer
This network shows the impact of papers produced by Tim Meyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tim Meyer. The network helps show where Tim Meyer may publish in the future.
Co-authors
The 25 scholars most cited alongside Tim Meyer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 228 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial Hit paper breakdown → | 2017 | 3563 |
| 2 | Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma Hit paper breakdown → | 2018 | 1893 |
| 3 | Hepatocellular carcinoma Hit paper breakdown → | 2022 | 1638 |
| 4 | Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial Hit paper breakdown → | 2017 | 1516 |
| 5 | Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma Hit paper breakdown → | 2020 | 960 |
| 6 | Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2018 | 827 |
| 7 | Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma Hit paper breakdown → | 2021 | 750 |
| 8 | Transarterial Therapy for Hepatocellular Carcinoma: Which Technique Is More Effective? A Systematic Review of Cohort and Randomized Studies Hit paper breakdown → | 2006 | 663 |
| 9 | Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs) Hit paper breakdown → | 2011 | 615 |
| 10 | A Systematic Review of Microvascular Invasion in Hepatocellular Carcinoma: Diagnostic and Prognostic Variability Hit paper breakdown → | 2012 | 543 |
| 11 | Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial Hit paper breakdown → | 2017 | 406 |
| 12 | Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines Hit paper breakdown → | 2021 | 359 |
| 13 | Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial Hit paper breakdown → | 2019 | 353 |
| 14 | EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma Hit paper breakdown → | 2024 | 347 |
| 15 | Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference Hit paper breakdown → | 2020 | 327 |
| 16 | Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial Hit paper breakdown → | 2023 | 313 |
| 17 | 2013 | 300 | |
| 18 | 2011 | 276 | |
| 19 | 2013 | 274 | |
| 20 | 2016 | 258 |
About Tim Meyer
Tim Meyer is a scholar working on Hepatology, Oncology, Epidemiology, Neurology and Immunology, having authored 228 papers that have together received 24.7k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (80 papers), Neuroendocrine Tumor Research Advances (45 papers), Lung Cancer Research Studies (25 papers), Neuroblastoma Research and Treatments (20 papers), Liver Disease Diagnosis and Treatment (15 papers), Cancer Immunotherapy and Biomarkers (13 papers), Pancreatic and Hepatic Oncology Research (13 papers) and Cancer Mechanisms and Therapy (10 papers). The work is most often cited by research in Hepatology (9.8k citations), Oncology (7.9k citations), Cancer Research (2.8k citations), Epidemiology (5.3k citations) and Pathology and Forensic Medicine (2.0k citations). Tim Meyer has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include Arndt Vogel, Andrew Kenneth Burroughs, Anna Lena Saborowski, Gonzalo Sapisochín, Riad Salem, Josep Maria Llovet, Gordon J.S. Rustin, Bruno Sangro, Martyn Evan Caplin and Tu Vinh Luong. Their work appears in journals such as Annals of Oncology, Journal of Hepatology, British Journal of Cancer, Clinical Cancer Research and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.